Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-X long-term extension of Iclepertin in schizophrenia
NL-OMON53746Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON53746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53746.